284 completed, 72 terminated, 36 recruiting, 31 unknown. 261 Phase 2, 138 Phase 1, 95 Phase 3, 23 Not applicable, 18 Phase 4.
Follow G-CSF: new trials by email Literature Review of G-CSF trials Research Report on G-CSF
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Ris-Rez, G-CSF - Sarcoma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 64 | 2026-06-22 | 2026-10-01 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-22 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 52 | 2026-05-01 | 2026-05-13 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation Thiotepa, Fludarabine, G-CSF - Hematologic Malignancies | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-02-20 | 2026-03-02 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus Sirolimus, Busulfan, Horse -Anti-thymocyte - Severe Combined Immune Deficiency (SCID) | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 | 2025-12-01 | |
| G-CSF-Related Bone Pain and Supportive Care Strategies in Patients With Solid Tumors Filgrastim (G-CSF), Naproxen, Loratadine - Solid Tumors, Chemotherapy-induced Neutropenia | Completed | Ankara Etlik City Hospital | 190 | 2025-09-27 | 2026-10-09 | |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-07-14 |
| Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies G-CSF, Decitabine, Venetoclax - Myeloid Malignancy, Hematologic Malignancy | Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2025-07-17 | 2026-03-04 |
| Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis. Darbepoetin, G-CSF, Lactulose - Decompensated Liver Cirrhosis | Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | 60 | 2025-06-04 | 2026-05-22 |
| Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia G-CSF, Antibiotics only - Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy | Phase 4 | Not yet recruiting | King Edward Medical University | 150 | 2025-06-01 | 2025-05-25 |
| PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PD-1 Inhibitors - Acute T Lymphoblastic Leukemia (T-ALL) | Phase 3 | Active not recruiting | Fujian Medical University Union Hospital | 40 | 2025-05-01 | 2026-04-21 |
Showing 20 of 479. Sign in to see all of them.
Leukemia, Myeloid, Acute (91) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Lymphoma (57) · Myelodysplastic Syndromes (53) · Leukemia (51) · Multiple Myeloma (48) · Hodgkin Disease (40) · Lymphoma, Non-Hodgkin (39) · Lymphoma, Large B-Cell, Diffuse (29) · Lymphoma, Mantle-Cell (29) · Leukemia, Lymphocytic, Chronic, B-Cell (26) · Neuroblastoma (26) · Burkitt Lymphoma (25) · Lymphoma, Follicular (24) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (20)
M.D. Anderson Cancer Center (58) · Children's Oncology Group (55) · National Cancer Institute (NCI) (41) · Masonic Cancer Center, University of Minnesota (22) · St. Jude Children's Research Hospital (22) · Fred Hutchinson Cancer Center (16) · Washington University School of Medicine (16) · University of Washington (14) · Northwestern University (12) · City of Hope Medical Center (11) · Alliance for Clinical Trials in Oncology (9) · Gynecologic Oncology Group (5) · Medical College of Wisconsin (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Post Graduate Institute of Medical Education and Research, Chandigarh (5)
United States (382) · Canada (58) · Australia (46) · China (29) · Puerto Rico (29) · Switzerland (22) · New Zealand (16) · Germany (14) · France (12) · Netherlands (12) · Spain (12) · India (9) · Italy (9) · United Kingdom (9) · Belgium (5)
Richard Burt, MD (10) · Brandon Triplett, MD (6) · Ashish Gupta, MBBS, MPH (3) · Dieter Hoelzer, MD,PhD (3) · Issa F. Khouri, MD,BS (3) · Pamela Becker (3) · Richard E. Champlin, MD (3) · Amar Gajjar, MD (2) · Anna Halpern (2) · Brandon M. Triplett, MD (2) · Carlos Rodriguez-Galindo (2) · Chitra M. Hosing, MD (2) · David H Barad, MD, MS (2) · Elias Jabbour (2) · Geoffrey Uy, M.D. (2)
PMID 37505794, PMID 19144982, PMID 22442346, PMID 22493293, PMID 22965967, PMID 27561722, PMID 28751559, PMID 33242441, PMID 34515338, PMID 36184192, PMID 37035316, PMID 40135712, PMID 10820362, PMID 15659500, PMID 15814645, PMID 16818281, PMID 16943538, PMID 17132719, PMID 17138821, PMID 17312330, PMID 17439836, PMID 18256325, PMID 18371107, PMID 18493992, PMID 18759768, PMID 18985718, PMID 18997171, PMID 19020548, PMID 19021050, PMID 19064966, PMID 19179301, PMID 19224841, PMID 19242495, PMID 19289999, PMID 19304957, PMID 19443658, PMID 19546405, PMID 19564636, PMID 19584400, PMID 19617208, PMID 19667400, PMID 19706886, PMID 19851858, PMID 19895612, PMID 19917845, PMID 20032498, PMID 20056794, PMID 20107229, PMID 20413658, PMID 20421455
U10CA098543 (29), U10CA180886 (14), U10CA031946 (12), P30CA016672 (11), P30CA015704 (9), U10CA027469 (8), U10CA032102 (8), P01CA081403 (4), P30CA033572 (4), U10CA021115 (4), P30CA006973 (3), U01CA097452 (3), U10CA180821 (3), U10CA180868 (3), U10CA180888 (3)